JP2009544742A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544742A5
JP2009544742A5 JP2009522029A JP2009522029A JP2009544742A5 JP 2009544742 A5 JP2009544742 A5 JP 2009544742A5 JP 2009522029 A JP2009522029 A JP 2009522029A JP 2009522029 A JP2009522029 A JP 2009522029A JP 2009544742 A5 JP2009544742 A5 JP 2009544742A5
Authority
JP
Japan
Prior art keywords
chromen
hydroxyphenyl
phenyl
methoxy
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009522029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544742A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/074665 external-priority patent/WO2008014497A2/en
Publication of JP2009544742A publication Critical patent/JP2009544742A/ja
Publication of JP2009544742A5 publication Critical patent/JP2009544742A5/ja
Withdrawn legal-status Critical Current

Links

JP2009522029A 2006-07-27 2007-07-27 嗜癖の治療におけるaldh−2阻害剤 Withdrawn JP2009544742A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83408306P 2006-07-27 2006-07-27
US84642806P 2006-09-21 2006-09-21
PCT/US2007/074665 WO2008014497A2 (en) 2006-07-27 2007-07-27 Aldh-2 inhibitors in the treatment of addiction

Publications (2)

Publication Number Publication Date
JP2009544742A JP2009544742A (ja) 2009-12-17
JP2009544742A5 true JP2009544742A5 (enExample) 2010-10-07

Family

ID=38792141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009522029A Withdrawn JP2009544742A (ja) 2006-07-27 2007-07-27 嗜癖の治療におけるaldh−2阻害剤

Country Status (14)

Country Link
US (1) US20080032995A1 (enExample)
EP (1) EP2046769A2 (enExample)
JP (1) JP2009544742A (enExample)
KR (1) KR20090033417A (enExample)
AU (1) AU2007278877A1 (enExample)
CA (1) CA2653056A1 (enExample)
CO (1) CO6210811A2 (enExample)
EC (1) ECSP088919A (enExample)
IL (1) IL195400A0 (enExample)
MA (1) MA30434B1 (enExample)
MX (1) MX2008015765A (enExample)
NO (1) NO20084971L (enExample)
RU (1) RU2008151762A (enExample)
WO (1) WO2008014497A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080207610A1 (en) * 2006-07-27 2008-08-28 Jeff Zablocki Aldh-2 inhibitors in the treatment of addiction
US8158810B2 (en) * 2006-07-27 2012-04-17 Gilead Sciences, Inc. ALDH-2 inhibitors in the treatment of addiction
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
WO2008112164A2 (en) 2007-03-08 2008-09-18 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CA2682207A1 (en) 2007-04-05 2008-10-16 Cv Therapeutics, Inc. Quinazolinone derivatives as aldh-2 inhibitors
EP2231149A2 (en) * 2007-11-06 2010-09-29 CV Therapeutics Inc. Aldh-2 inhibitors in the treatment of psychiatric disorders
JP2011510072A (ja) * 2008-01-24 2011-03-31 ギリアード・パロ・アルト・インコーポレイテッド 嗜癖の処置におけるaldh−2インヒビター
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
WO2010028175A1 (en) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
JP2012506856A (ja) * 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
EP2340292B1 (de) * 2008-10-29 2013-05-29 Merck Patent GmbH Flüssigkristallanzeige
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
BR112012019120A2 (pt) 2010-02-03 2016-06-28 Infinity Pharmaceuticais Inc forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
SI2533638T1 (sl) * 2010-02-12 2016-05-31 Nivalis Therapeutics, Inc. Novi inhibitorji S-nitrozoglutation reduktaze
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
US9063420B2 (en) 2013-07-16 2015-06-23 Rohm And Haas Electronic Materials Llc Photoresist composition, coated substrate, and method of forming electronic device
US9410016B2 (en) 2013-07-16 2016-08-09 Dow Global Technologies Llc Aromatic polyacetals and articles comprising them
US8933239B1 (en) 2013-07-16 2015-01-13 Dow Global Technologies Llc Bis(aryl)acetal compounds
US8962779B2 (en) 2013-07-16 2015-02-24 Dow Global Technologies Llc Method of forming polyaryl polymers
WO2019079209A1 (en) * 2017-10-16 2019-04-25 Amygdala Neurosciences, Inc. POLYTHERAPY FOR THE PREVENTION OF AN ADDICTION
JP7204568B2 (ja) * 2018-04-04 2023-01-16 株式会社Cics アミロイドβ疾患のホウ素中性子捕捉療法用化合物
CN109970738B (zh) * 2019-02-27 2021-07-09 上海工程技术大学 一种金雀花碱n-异黄酮类化合物及其制备方法及应用
EP4540228A1 (en) 2022-06-14 2025-04-23 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
JP2025520426A (ja) 2022-06-14 2025-07-03 アミグダラ ニューロサイエンシーズ, インコーポレイテッド Aldh-2阻害化合物及び使用方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907830A (en) * 1970-05-27 1975-09-23 Chinoin Gyogyszer Es Vegyeszet Isoflavone derivatives
US4166862A (en) * 1971-05-25 1979-09-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Animal feed containing anabolic isoflavones
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
DE2950135A1 (de) * 1979-12-13 1981-06-19 Merck Patent Gmbh, 6100 Darmstadt Basischer aether, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
US5679806A (en) * 1995-02-24 1997-10-21 Hauser, Inc. Process for the isolation and purification of isoflavones
US5783189A (en) * 1996-04-23 1998-07-21 Natural Pharmacia International, Inc. Method for treating alcohol dependence
US6255497B1 (en) * 1997-04-29 2001-07-03 The Endowment For Research In Human Biology, Inc. Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse
AU3899199A (en) 1998-05-12 1999-11-29 Endowment for Research in Human Biology, Inc., The Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
WO2004001058A2 (en) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
MXPA05000122A (es) * 2002-06-27 2005-12-14 Endowment For Res In Human Bio Compuestos utiles para la inhibicion de aldehido-deshidrogenasa.
CA2571421A1 (en) * 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
US8158810B2 (en) * 2006-07-27 2012-04-17 Gilead Sciences, Inc. ALDH-2 inhibitors in the treatment of addiction
US20080207610A1 (en) * 2006-07-27 2008-08-28 Jeff Zablocki Aldh-2 inhibitors in the treatment of addiction
CA2682207A1 (en) * 2007-04-05 2008-10-16 Cv Therapeutics, Inc. Quinazolinone derivatives as aldh-2 inhibitors
EP2231149A2 (en) * 2007-11-06 2010-09-29 CV Therapeutics Inc. Aldh-2 inhibitors in the treatment of psychiatric disorders

Similar Documents

Publication Publication Date Title
RU2008151762A (ru) Adlh-2 ингибиторы для лечения аддикции
RU2010122970A (ru) Ингибиторы aldh-2 при лечении психиатрических расстройств
ES2660571T3 (es) Inhibidores de la proteína tirosina fosfatasa humana y su uso farmacéutico
RU2492167C2 (ru) Производные аминотриазола в качестве агонистов alх
JP5261383B2 (ja) ヒトプロテインチロシンホスファターゼ阻害剤および使用法
JP2015533157A5 (enExample)
JP2013519680A5 (enExample)
CA2583217A1 (en) 1,3,4-thiadiazole compounds as protein kinase inhibitors
JP2019517455A5 (enExample)
JP2019052178A (ja) ブロモドメイン阻害剤としての新規の置換された二環式化合物
RU2018138707A (ru) Замещенные гетероарилом пиридины и способы применения
TWI705963B (zh) 作為dyrk激酶抑制劑之2,3-二氫苯并呋喃-5-基化合物
JP2009525984A5 (enExample)
JP2006503010A5 (enExample)
JP2018534328A5 (enExample)
HRP20120281T1 (hr) Derivati azabiciklo[3.1.0]heksana, korisni kao modulatori dopaminskih receptora d3
JP2012513958A (ja) 1,2,4−オキサジアゾール誘導体およびそれらの治療的使用
JP2020520354A5 (enExample)
RU2016111138A (ru) Гетероциклические соединения и способы их применения
JP2007523208A5 (enExample)
RU2012134306A (ru) Азотосодержащие производные гетероарилов
JP2011510985A5 (enExample)
JP2018507234A5 (enExample)
JP2014523400A5 (enExample)
JP2020073539A (ja) 線維症を処置するための方法及び医薬組成物